Compounds > 2-methyl-4-methoxyaniline
Page last updated: 2024-11-05

2-methyl-4-methoxyaniline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7610
CHEMBL ID1361784
CHEBI ID82430
SCHEMBL ID91981
MeSH IDM0105268

Synonyms (75)

Synonym
BIDD:GT0002
AC-2703
6-amino-3-methoxytoluene
NCIOPEN2_000112
nsc 66563
brn 0774727
2-amino-5-methoxytoluene
meta-cresidine
ccris 182
4-methoxy-o-toluidine
einecs 203-036-7
hsdb 7097
wln: zr b1 do1
2-methyl-4-methoxyaniline
nci-c02993
m-cresidine
p-anisidine, 2-methyl-
benzenamine, 4-methoxy-2-methyl-
nsc-66563
4-methoxy-2-methylaniline
2-methyl-p-anisidine
4-methoxy-2-methylbenzenamine
nsc66563
102-50-1
smr001216583
MLS001050129
inchi=1/c8h11no/c1-6-5-7(10-2)3-4-8(6)9/h3-5h,9h2,1-2h
NCGC00091371-01
4-methoxy-2-methylaniline, 98%
AKOS000150729
STL069534
1-amino-4-methoxy-2-methylbenzene
M1474
A19540
NCGC00091371-02
EN300-65896
C19376
4-methoxy-2-methyl-benzenamine
cas-102-50-1
dtxcid80349
NCGC00257370-01
dtxsid2020349 ,
tox21_303531
NCGC00258991-01
tox21_201440
4-amino-3-methylanisole
2-methyl-4-methoxybenzenamine
4-methoxy-2-methylphenylamine
4-methoxy-2-methyl-phenylamine
GEO-01690
unii-f0e8y56guk
f0e8y56guk ,
FT-0618877
AM20060188
(2-methyl-4-(methyloxy)phenyl)amine
m-cresidine [hsdb]
CL8401
SCHEMBL91981
CHEBI:82430 ,
PS-3574
4-methoxy-2-methyl aniline
4-methoxy 2-methylaniline
[2-methyl-4-(methyloxy)phenyl]amine
2-methyl-4-(methyloxy)aniline
2-methyl-4-methoxy aniline
2-methyl-4-methoxyphenylamine
CHEMBL1361784
4-methoxy-2-methyl-aniline
F0001-0069
W-108869
mfcd00007735
CS-W016518
Q27155934
SB30217
Z239604794
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methoxybenzenesAny aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency79.43280.631035.7641100.0000AID504339
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.69910.000229.305416,493.5996AID743075
gemininHomo sapiens (human)Potency0.58050.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.19 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cresidine
cresidine: structure		1.9610methoxybenzenes
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Experimental Neoplasms
[description not available]		01.9610